Biology subjects

Ticau, S.

Publications and source records attributed to Ticau, S..

5 recordsLinked to original sources

bioRxiv2023

Activin E is a TGFβ ligand that signals specifically through activin receptor-like kinase 7.

Activins are one of the three distinct subclasses within the greater Transforming Growth Factor {beta} (TGF{beta}) superfamily. First discovered for their critical roles in reproductive biology, activins have since been shown to alter cellular differentiation and proliferation. At present, members of the activin subclass include activin A (ActA), ActB, ActC, ActE, and the more distant members myostatin and GDF11. While the biological roles and signaling mechanisms of most activins class members have been well-studied, the signaling potential of ActE has remained largely unknown. Here, we characterized the signaling capacity of homodimeric ActE. Molecular modeling of the ligand:receptor complexes showed that ActC and ActE shared high similarity in both the type I and type II receptor binding epitopes. ActE signaled specifically through ALK7, utilized the canonical activin type II receptors, ActRIIA and ActRIIB, and was resistant to the extracellular antagonists follistatin and WFIKKN. In mature murine adipocytes, ActE invoked a SMAD2/3 response via ALK7, similar to ActC. Collectively, our results establish ActE as an ALK7 ligand, thereby providing a link between genetic and in vivo studies of ActE as a regulator of adipose tissue. SignificanceActivin E is a homodimeric member of the TGF{beta} family belonging to the activin subclass. Currently, the signaling capacity of ActE is unknown due to a lack of reliable reagents to study the protein. Here, we demonstrate that ActE acts as a canonical TGF{beta} ligand that signals through SMAD2/3 in an ALK7-dependent manner, similar to ActC. ActE also utilizes the activin type II receptors, ActRIIA and ActRIIB, to signal and is unable to be antagonized by FS288 and WFIKKN2. This study shows that ActE is a signaling ligand and provides a connection between genetic and in vivo studies that links ActE to adiposity.

biochemistry↗

bioRxiv2019

Widespread haploid-biased gene expression in mammalian spermatogenesis associated with frequent selective sweeps and evolutionary conflict

1Mendels first law dictates that alleles segregate randomly during meiosis and are distributed to offspring with equal frequency, requiring sperm to be functionally independent of their genetic payload. Developing mammalian spermatids have been thought to accomplish this by freely sharing RNA from virtually all genes through cytoplasmic bridges, equalizing allelic gene expression across different genotypes. Applying single cell RNA sequencing to developing spermatids, we identify a large class of mammalian genes whose allelic expression ratio is informative of the haploid genotype, which we call genoinformative markers (GIMs). 29% of spermatid-expressed genes in mice and 47% in non-human primates are not uniformly shared, and instead show a confident allelic expression bias of at least 2-fold towards the haploid genotype. This property of GIMs was significantly conserved between individuals and between rodents and primates. Consistent with the interpretation of specific RNA localization resulting in incomplete sharing through cytoplasmic bridges, we observe a strong depletion of GIM transcripts from chromatoid bodies, structures involved in shuttling RNA across cytoplasmic bridges, and an enrichment for 3 UTR motifs involved in RNA localization. If GIMs are translated and functional in the context of fertility, they would be able to violate Mendels first law, leading to selective sweeps through a population. Indeed, we show that GIMs are enriched for signatures of positive selection, accounting for dozens of recent mouse, human, and primate selective sweeps. Intense selection at the sperm level risks evolutionary conflict between germline and somatic function, and GIMs show evidence of avoiding this conflict by exhibiting more testis-specific gene expression, paralogs, and isoforms than expression-matched control genes. The widespread existence of GIMs suggests that selective forces acting at the level of individual mammalian sperm are much more frequent than commonly believed. 2 Authors summaryMendels first law dictates that alleles are distributed to offspring with equal frequency, requiring sperm carrying different genetics to be functionally equivalent. Despite a small number of known exceptions to this, it is widely believed that sharing of gene products through cytoplasmic bridges erases virtually all differences between haploid sperm. Here, we show that a large class of mammalian genes are not completely shared across these bridges, therefore causing sperm phenotype to correspond partly to haploid genotype. We term these genes "genoinformative markers" (GIMs) and show that their identity tends to be conserved from rodents to primates. Because some GIMs can link sperm genotype to function, they can be thought of as selfish genetic elements which lead to natural selection between sperm rather than between organisms, a violation of Mendels first law. We find evidence of this biased inheritance, showing that GIMs are strongly enriched for selective sweeps that spread alleles through mouse and human populations. For genes expressed both in sperm and in somatic tissues, this can cause a conflict because optimizing gene function for sperm may be detrimental to its other functions. We show that there is evolutionary pressure to avoid this conflict, as GIMs are strongly enriched for testis-specific gene expression, testis-specific paralogs, and testis-specific isoforms. Therefore, GIMs and sperm-level natural selection may provide an elegant explanation for the peculiarity of testis gene expression patterns, which are an extreme outlier relative to all other tissues.

genetics↗

bioRxiv2019

Transthyretin-stabilizing mutation T119M is not associated with protection against vascular disease or death in the UK Biobank

BackgroundDestabilized transthyretin (TTR) can result in the progressive, fatal disease transthyretin-mediated (ATTR) amyloidosis. A stabilizing TTR mutation, T119M, is the basis for a therapeutic strategy to reduce destabilized TTR. Recently, T119M was associated with extended lifespan and lower risk of cerebrovascular disease in a Danish cohort. We aimed to determine whether this finding could be replicated in the UK Biobank.\n\nMethodsTTR T119M carriers were identified in the UK Biobank, a large prospective cohort of [~]500,000 individuals. Association between T119M genotype and inpatient diagnosis of vascular disease, cardiovascular disease, cerebrovascular disease, and mortality was analyzed.\n\nResultsFrequency of T119M within the white UK Biobank population (n=337,148) was 0.4%. Logistic regression comparing T119M carriers to non-carriers found no association between T119M and vascular disease (odds ratio [OR]=1.08; p=.27), cardiovascular disease (OR=1.08; p=.31), cerebrovascular disease (OR=1.1; p=.42), or death (OR=1.2; p=.06). Cox proportional hazards regression showed similar results (hazard ratio>1, p>.05). Age at death and vascular disease diagnosis were similar between T119M carriers and non-carriers (p=.12 and p=.38, respectively).\n\nConclusionsThere was no association between the TTR T119M genotype and risk of vascular disease or death in a large prospective cohort study, indicating that TTR tetramer stabilization through T119M is not protective in this setting.

genetics↗

bioRxiv2019

Deep phenotyping of a healthy human HAO1 knockout informs therapeutic development for primary hyperoxaluria type 1.

Primary Hyperoxaluria Type 1 (PH1) is a rare autosomal recessive metabolic disorder of oxalate metabolism leading to kidney failure as well as multi-organ damage. Overproduction of oxalate occurs in the liver due to an inherited genetic defect in the enzyme alanine-glyoxylate aminotransferase (AGXT), causing pathology due to the insolubility of calcium oxalate crystals in body fluids. The main current therapy is dual liver-kidney transplant, which incurs high morbidity and has poor availability in some health systems where PH1 is more prevalent. One approach currently in active clinical investigation targets HAO1 (hydroxyacid oxidase 1), encoding glycolate oxidase, to reduce substrate levels for oxalate production. To inform drug development, we sought individuals with reduced HAO1 function due to naturally occurring genetic variation.\n\nAnalysis of loss of function variants in 141,456 sequenced individuals suggested individuals with complete HAO1 knockout would only be observed in 1 in 30 million outbred people. However in a large sequencing and health records program (Genes & Health), in populations with substantial autozygosity, we identified a healthy adult individual predicted to have complete knockout of HAO1 due to an ultra rare homozygous frameshift variant (rs1186715161, ENSP00000368066.3:p.Leu333SerfsTer4). Primary care and hospital health records confirmed no apparently related clinical phenotype. At recall, urine and plasma oxalate levels were normal, however plasma glycolate levels (171 nmol/mL) were 12 times the upper limit of normal in healthy, reference individuals (mean+2sd=14 nmol/mL, n=67) while her urinary glycolate levels were 6 times the upper limit of normal. Comparison with preclinical and phase 1 clinical trial data of an RNAi therapeutic targeting HAO1 (lumasiran) suggests the individual likely retains <2% residual glycolate oxidase activity.\n\nThese results provide important data to support the safety of HAO1 inhibition as a potential chronic therapy for a devastating metabolic disease (PH1). We also suggest that the effect of glycolate oxidase suppression in any potential other roles in humans beyond glycolate oxidation do not lead to clinical phenotypes, at least in this specific individual. This demonstrates the value of studying the lifelong complete knockdown of a target protein in a living human to aid development of a potential therapeutic, both in de-risking the approach and providing potential hypotheses to optimize its development. Furthermore, therapy for PH1 is likely to be required lifelong, in contrast to data from chronicity studies in non-human species or relatively short-term therapeutic studies in people. Our approach demonstrates the potential for improved drug discovery through unlocking relevant evidence hiding in the diversity of human genetic variation.

genetics↗

bioRxiv2018

Baculovirus AC102 is a nucleocapsid protein that is crucial for nuclear actin polymerization and nucleocapsid morphogensis

The baculovirus Autographa californica multiple nucleopolyhedrovirus (AcMNPV), the type species of alphabaculoviruses, is an enveloped DNA virus that infects lepidopteran insects and is commonly known as a vector for protein expression and cell transduction. AcMNPV belongs to a diverse group of viral and bacterial pathogens that target the host cell actin cytoskeleton during infection. AcMNPV is unusual, however, in that it absolutely requires actin translocation into the nucleus early in infection, and actin polymerization within the nucleus late in infection coincident with viral replication. Of the six viral factors that are sufficient, when coexpressed, to induce the nuclear localization of actin, only AC102 is essential for viral replication and the nuclear accumulation of actin. We therefore sought to better understand the role of AC102 in actin mobilization in the nucleus early and late in infection. Although AC102 was thought to function early in infection, we found that AC102 is predominantly expressed as a late protein. In addition, we observed that AC102 is required for F-actin assembly in the nucleus during late infection, as well as for proper formation of viral replication structures and nucleocapsid morphogenesis. Finally, we found that AC102 is a nucleocapsid protein and a newly recognized member of a complex consisting of the viral proteins EC27, C42, and the actin polymerization protein P78/83. Taken together, our findings suggest that AC102 is necessary for nucleocapsid morphogenesis and actin assembly during late infection through its role as a component of the P78/83-C42-EC27-AC102 protein complex.\n\nIMPORTANCEThe baculovirus Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is an important biotechnological tool for protein expression and cell transduction, and related nucleopolyhedroviruses are also employed as environmentally benign insecticides. One impact of our work is to better understand the fundamental mechanisms through which AcMNPV exploits the cellular machinery of the host for replication, which may aid in the development of improved baculovirus-based research and industrial tools. Moreover, AcMNPVs ability to mobilize the host actin cytoskeleton within the cells nucleus during infection makes it a powerful cell biological tool. It is becoming increasingly clear that actin plays important roles in the cells nucleus, yet the regulation and function of nuclear actin is poorly understood. Our work to better understand how AcMNPV relocalizes and polymerizes actin within the nucleus may reveal fundamental mechanisms that govern nuclear actin regulation and function, even in the absence of viral infection.

microbiology↗